Anthony W Orr

US Patent:

20210401898, Dec 30, 2021

Filed:

Apr 12, 2021

Appl. No.:

17/228276

Inventors:

- Baton Rouge LA, US
Mansoureh BARZEGAR - Lafayette LA, US
Yuping WANG - Shreveport LA, US
Anthony Wayne ORR - Benton LA, US
Mabruka ALFAIDI - Shreveport LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 35/50
C12N 5/0775

Abstract:

Therapeutics and methods for treating a stroke in a human comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of immortalized human placenta mesenchymal stem cells (hPMSCs) and a product from the immortalized hPMSCs. Methods and therapeutic products comprising extracellular vesicles (EVs) isolated from of immortalized hPMSCs. Therapeutics and methods of treating COVID-19 disease vascular injury comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of hPMSCs and a product from the hPMSCs.

US Patent:

20210379016, Dec 9, 2021

Filed:

Jun 7, 2021

Appl. No.:

17/341249

Inventors:

- Baton Rouge LA, US
Christopher KEVIL - Shreveport LA, US
Anthony Wayne ORR - Benton LA, US
Chowdhury S ABDULLAH - Shreveport LA, US
Richa Aishwarya - Shreveport LA, US

Assignee:

Board of Supervisors of Louisiana State University and Agricultural and Mechanical College - Baton Rouge LA

International Classification:

A61K 31/4015
A61K 45/06
A61K 31/55
A61K 31/5375
A61K 31/341
A61K 31/445
A61K 31/57

Abstract:

Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.

US Patent:

20180051289, Feb 22, 2018

Filed:

Aug 18, 2017

Appl. No.:

15/681331

Inventors:

- Baton Rouge LA, US
Anthony Wayne ORR - Benton LA, US

International Classification:

C12N 15/113
C12N 15/115
A61K 48/00
A61K 9/00
A61K 45/06

Abstract:

A method of treating a condition in a mammal comprising administering a pharmacologically effective amount of a therapeutic, wherein the therapeutic one of increases EphA2 expression and supplements ephrin type-A receptor 2, and the condition is one of fatty liver disease, elevated plasma cholesterol level, and elevated plasma triglyceride level.